Loading...
NPI 1215055256 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Elite Clinical Laboratory, Inc is a clinical medical laboratory provider located in Houston, Texas. This profile covers 65 Medicare and 62 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Elite Clinical Laboratory, Inc |
| Address | 3600 S Gessner Rd Ste 110 |
| City | Houston |
| State | TX |
| ZIP | 77063 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 27, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3M |
| Medicaid | $366.9K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
65 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 460 | $660 | $306.3K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 490 | $590 | $288.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 420 | $660 | $279.8K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 470 | $590 | $276.9K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 420 | $630 | $262.3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 870 | $240 | $210.5K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 420 | $490 | $203.4K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 60 | $2,400 | $148.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,720 | $30 | $126.4K |
| 81430 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 60 genes, including 16 genes that the code descriptor lists, which may… | 60 | $1,590 | $89.2K |
Showing 1–10 of 65
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
65 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81185 | 9 | 10 | 110 | $820 | $906.1K |
| 81419 | 6 | 10 | 80 | $2,400 | $666.2K |
| 81302 | 7 | 10 | 90 | $520 | $479.9K |
| 87150 | 28 | 30 | 1,260 | $30 | $430.3K |
| 81317 | 5 | 20 | 220 | $660 | $382.7K |
| 81298 | 5 | 20 | 220 | $630 | $362.7K |
| 81307 | 5 | 20 | 150 | $660 | $361.4K |
| 81249 | 4 | 20 | 80 | $590 | $319.2K |
| 81238 | 4 | 20 | 110 | $590 | $281.7K |
| 81309 | 9 | 10 | 110 | $270 | $278.9K |
Showing 1–10 of 65
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
62 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,360 | $80 | $181.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,820 | $20 | $32.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,060 | $20 | $24.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,210 | $10 | $17.7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,330 | $10 | $16.3K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 1,250 | $10 | $8.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 2,130 | $1 | $8.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,060 | $10 | $8.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,230 | $1 | $6.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 2,140 | $1 | $6.4K |
Showing 1–10 of 62
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
62 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 19 | 20 | 180 | $200 | $923K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 117 | 340 | 400 | $50 | $553.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 58 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 223 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 123 | 300 | 410 | $20 | $223.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 23 | 140 | 180 | $60 | $215.9K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 130 | 150 | 320 | $20 | $184K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 22 | 100 | 650 | $50 | $161.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 106 | 260 | 640 | $20 | $137.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 85 | 350 | 230 | $70 | $120.3K |
Showing 1–10 of 62
Other providers in the same ZIP code as Elite Clinical Laboratory, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| M. Winter & Associates Pediatric Therapy Centers, Ltd | TX | Rehabilitation Clinic/Center | $0 | $32.1M |
| Jaimel Health Care Service LLC | TX | Home Health Agency | $0 | $27.2M |
| Just Real Kare, Inc | TX | Personal Care Attendant | $0 | $26.3M |
| Vita-living, Inc. | TX | Case Management Agency | $0 | $19M |
| Houston Therapy Consult PLLC | TX | Home Health Agency | $0 | $18.7M |
| Restore Health Care Services,inc. | TX | Home Health Agency | $0 | $14.8M |
| Outreach Health Community Care Services, Lc | TX | Home Health Agency | $0 | $12.4M |
| Belltech Enterprises, Inc. | TX | Home Health Agency | $0 | $12.2M |
| Physicians Ambulatory Surgery Center, LLC | TX | Ambulatory Surgical Clinic/Center | $794.6K | $830 |
| Stuart Nathan | TX | Clinical Psychologist | $518.1K | $21K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.